Investor Presentaiton
Key development milestones
Diabetes
Investor Presentation
First six months of 2018
Slide 13
•
•
OzempicⓇ label updated in the EU to reflect updated device offering
XultophyⓇ label updated in the EU based on LEADER and DEVOTE data
Successful completion of additional four phase 3a trials, PIONEER 2, 3, 4 and 7, with oral semaglutide
Updated CVOT plans for OzempicⓇ and oral semaglutide to potentially use a bridging strategy between
SUSTAIN 6 and PIONEER 6 trials to obtain CV label for OzempicⓇ
Phase 3b trial with VictozaⓇ as add-on to any SGLT2 inhibitor successfully completed
Phase 3b trial Ellipse with Victoza® in children and adolescents (10-17 years) successfully completed
Obesity
The four phase 3a, STEP trials, with injectable semaglutide 2.4 mg for people with obesity initiated
Following the obesity portfolio review, FGF-21 and G530L have been discontinued
Biopharma
RefixiaⓇ approved in Japan, with a broad label for people with blood coagulation factor IX deficiency
Positive results from phase 2 trial with somapacitan for treatment of children with growth hormone deficiency
changing
diabetes
novo nordiskView entire presentation